Basic HTML Version
92
SCIENTIFIC REPORT 2012
Title:
Multicenter, open-label, single-group study of pertuzumab in
combination with trastuzumab and a Texan as first-line treatment of patients with
advanced breast cancer (metastatic or locally recurrent) HER2 positive.
District Attorney:
F. Hoffmann-La Roche Ltd.
Principal Investigator:
Elsa Dalmau Pórtulas.
Title:
Multicenter, single-group study of trastuzumab emtansin
(TDM1) in patients with locally advanced or metastatic breast cancer, HER2 positive,
who have previously received treatment based on an anti-HER2 agent and chemotherapy.
District Attorney:
F. Hoffmann - La Roche Ltd.
Principal Investigator:
Elsa Dalmau Pórtulas.
Title:
Phase III multinational, randomized, open cost study (TV-1011 / OGX-011) in
combination with docetaxel versus docetaxel as second-line treatment in patients
with advanced or mestastatic microcytic lung cancer (stage IV).
Promotor
: Teva Pharmaceutical Industries, Ltd
.
Principal Investigator:
Elsa Dalmau Pórtulas.
Title:
Phase II randomized study of oral vinorelbine and cisplatin followed by
maintenance with oral vinorelbine as the sole agent against gemcitabine and cisplatin
followed by maintenance with gemcitabine as the sole first-line agent in patients
with locally advanced microcytic or metastatic lung cancer with histological type
scaly.
District Attorney:
Pierre Fabre Ibérica SA
Principal Investigator:
Elsa Dalmau Pórtulas.
Title:
Prospective, non - randomized, open - label, two - phase, phase III study
multinational to ensure the security of assisted administration or self - administration of
subcutaneous trastuzumab as an adjuvant treatment in patients with breast cancer
early operable HER 2+.
District Attorney:
F. Hoffmann-La Roche Ltd.
Principal Investigator:
Luis Fernandez Morales.
Title:
Association of insulin resistance with complete pathological response to chemotherapy
neoadjuvant in patients with operable breast cancer.
District Attorney:
Dr. Alejandra Armengol Alonso.
Principal Investigator:
Luis Fernandez Morales.